Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 43, Issue 11, 2016, Pages 2084-2097

  Madsen, Poul Henning ^a   Holdgaard, Paw Christian ^a   Christensen, Janne Buck ^b   Høilund Carlsen, Poul Flemming ^b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

18 F PET CT; Endobronchial ultrasound; Lung cancer; Solitary pulmonary nodule

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; INVASIVE PROCEDURE; LUNG BIOPSY; LUNG CANCER; LUNG NODULE; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; METASTASIS; PREOPERATIVE EVALUATION; REVIEW; SYSTEMATIC REVIEW; THORACOTOMY; TUMOR DIFFERENTIATION; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PREVALENCE; PROCEDURES; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA;

EARLY DETECTION OF CANCER; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PREVALENCE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84966659622     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-016-3407-4     Document Type: Review

References (84)

1. Han Y, Xiao H, Zhou Z, Yuan M, Zeng Y, Wu H, et al. Cost-effectiveness analysis of strategies introducing integrated 18F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer. Nucl Med Commun. 2015;36:234–41.
2. Region Syddanmark. PET/CT i Region Syddanmark. http://ipaper.ipapercms.dk/RegionSyddanmark/OUH/Stabsafdelinger/Afdelingen_for_Kvalitet_og_Forskning___MTV/140519_PETCT_Undergruppens_afrapportering_Samlet_v4/. Date last updated: April 2014. Date last assessed: February 9 2015.
3. Stevens AN. Development of PET in Western Europe (abstract OP 104). Eur J Nucl Med Mol Imaging. 2013;40 Suppl 2:S1–477.
4. Kotzerke J, Oehme L, Grosse J, Hellwig D. Positron emission tomography 2013 in Germany. Results of the query and current status. Nuklearmedizin. 2015;54(2).
5. Dansk Lunge Cancer Gruppe. Lungecancer: Visitation, diagnose & stadieinddeling. www.lungecancer.dk. Date last updated: January 21 2015. Date last assessed: February 9 2015.
6. National Institute for Health and Care Excellence. Lung cancer: Diagnosis and treatment. https://www.nice.org.uk/guidance/cg121. Date last updated: April 2011. Date last assessed February 9 1015.
7. National Comprehensive Cancer Network. Non-small cell lung cancer. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Date last updated: April 2014. Date last assessed: February 9 2015.
8. European Respiratory Society. http://www.ers-education.org/guidelines.aspx. Date last updated: not available. Date last assessed: February 10 2015.
9. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e93S–120.
10. Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e437S–54.
11. Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S–50.
12. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e142S–65.
13. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45:787–98.
14. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii56–64.
15. Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi89–98.
16. American Cancer Society. Cancer facts and figures 2014. www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Date last updated: 2014. Date last assessed: February 9 2015.
17. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126(5):376–80.
18. Centre for Evidence Based Medicine. Finding the evidence 1 – Using PICO to formulate a search question. http://www.cebm.net/finding-the-evidence-1-using-pico-to-formulate-a-search-question/. Date last updated: 2014. Date last assessed: February 9 2015.
19. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26(2):91–108.
20. Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries: the evolution of a rapid review approach. Syst Rev. 2012;1:10.
21. Khangura S, Polisena J, Clifford TJ, Farrah K, Kamel C. Rapid review: an emerging approach to evidence synthesis in health technology assessment. Int J Technol Assess Health Care. 2014;30(1):20–7.
22. Varker T, Forbes D, Dell L, Weston A, Merlin T, Hodson S, et al. Rapid evidence assessment: increasing the transparency of an emerging methodology. J Eval Clin Pract. 2015 [E-pub ahead of print].
23. Civil Service. What is a rapid evidence assesement? http://www.civilservice.gov.uk/networks/gsr/resources-and-guidance/rapid-evidence-assessment/what-is. Date last updated: N/A. Date last assessed: July 29 2015.
24. Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11(44):iii-iv, xi-267.
25. Centre for Evidence Based Medicine. Oxford Centre for Evidence-based Medicine – Levels of evidence (March 2009). http://www.cebm.net/index.aspx?o=1025. Date last updated: 2014. Date last assessed: February 9 2015.
26. Fletcher JW, Kymes SM, Gould M, Alazraki N, Coleman RE, Lowe VJ, et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008;49:179–85.
27. Harders SW. LUCIS: lung cancer imaging studies. DMJ. 2012;59(11):B4542.
28. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer. 2004;45:19–27.
29. Yi CA, Lee KS, Kim BT, Choi JY, Kwon OJ, Kim H, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med. 2006;47:443–50.
30. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38:261–6.
31. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med. 2002;29:1166–73.
32. Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. AJM Am J Roentgenol. 2006;187:1361–7.
33. Kagna O, Solomonov A, Keidar Z, Bar-Shalom R, Fruchter O, Yigla M, et al. The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer. Eur J Nucl Med Mol Imaging. 2009;36:997–1004.
34. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest. 2007;131:255–60.
35. Herder GJ, Golding RP, Hoekstra OS, Comans EF, Teule GJ, Postmus PE, et al. The performance of (18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2004;31:1231–6.
36. Bar-Shalom R, Kagna O, Israel O, Guralnik L. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography. Cancer. 2008;113:3213–21.
37. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007;48:214–20.
38. Jeong SY, Lee KS, Shin KM, Bae YA, Kim BT, Choe BK, et al. Efficacy of PET/CT in the characterization of solid or partly solid solitary pulmonary nodules. Lung Cancer. 2008;61:186–94.
39. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest. 1995;108:441–6.
40. Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol. 2006;24:1800–6.
41. Kozower BD, Meyers BF, Reed CE, Jones DR, Decker PA, Putnam Jr JB. Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thoracic Surg. 2008;85:1166–70.
42. Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol. 2004;22:2357–62.
43. Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221–8.
44. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. New Engl J Med. 2009;361:32–9.
45. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncology Biol Phys. 2001;50:287–93.
46. Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thoracic Cardiovasc Surg. 2003;126:1943–51.
47. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. New Engl J Med. 2003;348:2500–7.
48. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17:23–32.
49. Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, et al. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer. J Clin Oncol. 2005;23:6846–53.
50. Darling GE, Maziak DE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol. 2011;6:1367–72.
51. Herth FJ, Eberhardt R, Krasnik M, Ernst A. Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest. 2008;133:887–91.
52. Fischer BM, Mortensen J, Hansen H, Vilmann P, Larsen SS, Loft A, et al. Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax. 2011;66:294–300.
53. Bryant AS, Cerfolio RJ, Klemm KM, Ojha B. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thoracic Surg. 2006;82:417–22.
54. Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. Chest. 2006;130(6):1791–5.
55. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology. 2005;236:1011–9.
56. Gonzalez-Stawinski GV, Lemaire A, Merchant F, O’Halloran E, Coleman RE, Harpole DH, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thoracic Cardiovasc Surg. 2003;126:1900–5.
57. Stroobants SG, D’Hoore I, Dooms C, De Leyn PR, Dupont PJ, De Wever W, et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin Lung Cancer. 2003;4:242–7.
58. Lu Y, Xie D, Huang W, Gong H, Yu J. 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. Neoplasma. 2010;57:129–34.
59. Ozcan Kara P, Kara T, Kara Gedik G, Kara F, Sahin O, Ceylan Gunay E, et al. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun. 2011;32:106–12.
60. Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E, et al. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardio Thoracic Surg. 2008;33:104–9.
61. Kumar R, Xiu Y, Yu JQ, Takalkar A, El-Haddad G, Potenta S, et al. 18F 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med. 2004;45:2058–62.
62. Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47:32–7.
63. Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin Lung Cancer. 2001;3:59–64.
64. Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007;84:177–81.
65. Salomaa ER, Sallinen S, Hiekkaen H, Liippo K. Delays in the diagnosis and treatment of lung cancer. Chest. 2005;128:2282–8.
66. Kim JI, Park CM, Lee SM, Goo JM. Rapid needle-out patient-rollover approach after cone beam CT-guided lung biopsy: effect on pneumothorax rate in 1,191 consecutive patients. Eur Radiol. 2015;25:1845–53.
67. Boskovic T, Stanic J, Pena-Karan S, Zarogoulidis P, Drevelegas K, Katsikogiannis N, et al. Pneumothorax after transthoracic needle biopsy of lung lesions under CT guidance. J Thorac Dis. 2014;6:S99–107.
68. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932–45.
69. Hoetjes NJ, van Velden FHP, Hoekstra OS, Hoekstra CJ, Krak NC, Lammertsma AA, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging. 2010;37(9):1679–87.
70. Salavati A, Borofsky S, Boon-Keng TK, Houshmand S, Khiewvan B, Saboury B, et al. Application of partial volume effect correction and 4D PET in the quantification of FDG avid lung lesions. Mol Imaging Biol. 2015;17(1):140–8.
71. Naidich DP, Bankier AA, MacMahon H, Schaefer-Prokop CM, Pistolesi M, Goo JM, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology. 2013;266:304–17.
72. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology. 2005;237:395–400.
73. Gaeta M, Volta S, Scribano E, Loria G, Vallone A, Pandolfo I. Air-space pattern in lung metastasis from adenocarcinoma of the GI tract. J Comput Assist Tomogr. 1996;2:300–4.
74. Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Recent results of postoperative mortality for surgical resections in lung cancer. Ann Thorac Surg. 2004;7:999–1002.
75. Truong MT, Pan T, Erasmus JJ. Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging. J Thorac Imaging. 2006;21:111–22.
76. Smoragiewicz M, Laskin J, Wilson D, Ramsden K, Yee J, Lam S, et al. Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review. Curr Oncol. 2014;21(6):e768–74.
77. Halaç M, Özhan M, Yilmaz Aksoy S, Vatankulu B, Aliyev A, Asa S, et al. The role of FDG-PET/CT in detecting unsuspected and unknown distant metastasis in the initial staging of NSCLC. Turk J Med Sci. 2014;44(6):1029–40.
78. Dalli A, Selimoglu Sen H, Coskunsel M, Komek H, Abakay O, Sergi C, et al. Diagnostic value of PET/CT in differentiating benign from malignant solitary pulmonary nodules. J BUON. 2013;18(4):935–41.
79. Harders SW, Madsen HH, Hjorthaug K, Arveschoug AK, Rasmussen TR, Meldgaard P, et al. Mediastinal staging in non-small-cell lung carcinoma: computed tomography versus F-18-fluorodeoxyglucose positron-emission tomography and computed tomography. Cancer Imaging. 2014;14:23.
80. Al-Hakami HA, Makis W, Anand S, Mlynarek A, Black MJ, Stern J, et al. Head and neck incidentalomas on positron emission tomographic scanning: ignore or investigate? J Otolaryngol Head Neck Surg. 2011;40:384–90.
81. Shie P, Cardarelli R, Sprawls K, Fulda KG, Taur A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009;30:742–8.
82. Chae EY, Cha JH, Kim HH, Shin HJ, Kim HJ, Oh HY, et al. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis. Acta Radiol. 2012;53:530–5.
83. Treglia G, Calcagni ML, Rufini V, Leccisotti L, Meduri GM, Spitilli MG, et al. Clinical significance of incidental focal colorectal 18F-fluorodeoxyglucose uptake: our experience and a review of the literature. Colorectal Dis. 2011;14:174–80.
84. Hess S, Blomberg BA, Zhu HJ, Høilund-Carlsen PF, Alavi A. The pivotal role of FDG-PET/CT in modern medicine. Acad Radiol. 2014;21:232–49.